LEGN Legend Biotech Corporation
Legend Biotech Corporation (LEGN) is expected to report earnings on February 9, 2027, before the market open. The consensus earnings estimate is $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -25.0% since its last earnings release on November 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Legend Biotech Corporation
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.